Stem Cell Therapy for ALS: What the Evidence Shows and Why Trials Matter
ALS (amyotrophic lateral sclerosis) is among the cruelest diagnoses in medicine — progressive, fatal, with a median survival of 2–5 years from symptom onset. The desperation this creates makes ALS patients particularly vulnerable to unproven therapies. This article is written with deep respect for that desperation, and an equally deep commitment to honesty about what the evidence does and does not show.
The NurOwn Story: A Cautionary Tale
BrainStorm Cell Therapeutics' NurOwn was the most advanced stem cell therapy for ALS. The approach used the patient's own bone marrow MSCs, modified in the lab to secrete neurotrophic factors (NTF-secreting MSCs), then injected intrathecally (into the spinal fluid). The Phase III trial randomized 189 patients with early ALS (ALSFRS-R score ≥25, disease duration ≤2 years).
The primary endpoint — percentage of responders on the ALSFRS-R slope — was not met (34.6% NurOwn vs. 27.7% placebo, p=0.45). A pre-specified subgroup of early-disease patients showed a nominally significant benefit, but this was not sufficient for approval. The FDA issued a Complete Response Letter in September 2023.
The NurOwn Phase III failure is sobering but instructive. It does not mean stem cells cannot help ALS — it means this specific approach, at this specific dose and timing, did not demonstrate sufficient efficacy in the overall trial population. The field continues to evolve.
Active Trials Worth Knowing About
| Program | Sponsor | Cell Type | Delivery | Phase | Status (2026) |
|---|---|---|---|---|---|
| NurOwn | BrainStorm | Autologous NTF-MSCs | Intrathecal | III | Additional studies planned |
| AB126 | Amylyx/Healey | Neural progenitor cells | Intraspinal | I/IIa | Recruiting |
| Q-Cell (NSI-566) | Q Therapeutics | Human neural stem cells | Intraspinal | II | Ongoing |
| HDIT/HSCT | Academic | Hematopoietic (immune reset) | IV post-conditioning | I/II | Early data |
| Allogeneic UC-MSC | Various | Umbilical cord MSCs | Intrathecal + IV | I/II | Multiple small trials |
Why Clinical Trials Should Come First
For ALS patients specifically, we advocate exhausting clinical trial options before pursuing commercial stem cell therapy abroad. Here is why:
- Rigorous monitoring: ALS trials include frequent neurological assessments, pulmonary function testing, and imaging that track disease progression precisely — something commercial clinics cannot replicate.
- No cost: Trial treatments are provided at no charge, and many trials cover travel expenses for participants.
- Specialized delivery: The most promising ALS approaches use intrathecal or intraspinal delivery, requiring neurosurgical expertise that general regenerative clinics lack.
- Contribution to science: Every trial participant helps build the evidence base that will determine whether future ALS patients have an effective treatment.
- Access to cutting-edge approaches: Trial therapies (NTF-MSCs, neural progenitor cells) are specifically engineered for neurodegeneration, unlike the general-purpose MSCs available commercially.
The ALS Association maintains a searchable trial database at als.org/research/clinical-trials. ClinicalTrials.gov lists all registered studies. The Northeast ALS Consortium (NEALS) coordinates multi-site trials. Your ALS clinic coordinator can help match you to eligible trials.
What Commercial MSC Therapy Can and Cannot Offer for ALS
Some Colombian and other international clinics offer MSC infusions (typically IV and sometimes intrathecal) for ALS patients. Based on published literature:
- What is plausible: Transient slowing of disease progression in some patients (published case series from Jordan, China, and Mexico report stabilization of ALSFRS-R scores for 3–6 months in select patients)
- What is not demonstrated: Disease reversal, restoration of lost motor function, or long-term survival extension
- What is unrealistic: Any claim of "cure" or significant functional recovery
NurOwn Phase III trial data (2023). Primary endpoint not met; subgroup analysis showed trend favoring early intervention.
The Honest Conversation
If you or a loved one has ALS and is considering stem cell therapy, here is a framework:
- First, confirm you are on optimal standard treatment: riluzole, edaravone/Radicava (if eligible), multidisciplinary clinic care.
- Second, actively explore clinical trials through your ALS clinic, NEALS, and ClinicalTrials.gov. New trials open regularly.
- Third, if no trials are available or accessible, and you choose to pursue commercial MSC therapy, select a clinic that is honest about the limitations, uses intrathecal delivery (more relevant for neurodegeneration than IV alone), provides pre/post ALSFRS-R scoring, and does not promise reversal of the disease.
Frequently Asked Questions
No. No stem cell therapy has demonstrated the ability to cure ALS in any published study. The most optimistic results show temporary slowing of disease progression in some patients. ALS remains a fatal neurodegenerative disease, and any clinic claiming a cure is not being truthful.
The trial did not meet its pre-specified primary endpoint in the overall population. However, a subgroup of patients with earlier-stage disease showed a meaningful response. This suggests that timing and patient selection may be critical — a lesson that will inform future trial design.
The scientific consensus favors intrathecal (spinal fluid) or intraspinal delivery for neurological conditions. IV-infused MSCs must cross the blood-brain barrier, which limits delivery to the central nervous system. Intrathecal injection bypasses this barrier. However, intrathecal delivery requires specialized expertise and carries its own procedural risks.
Typical pricing for MSC protocols targeting neurological conditions ranges from $12,000 to $22,000 in Colombia, depending on cell type, delivery method (IV vs. intrathecal), and number of treatments. This compares to $25,000–$50,000+ at US cash-pay centers.
Not exactly. The science behind MSCs for neurodegeneration is legitimate, and multiple respected institutions are running trials. However, the gap between scientific plausibility and proven clinical benefit is real. Your clinic is right to be cautious, especially about commercial offerings that overstate the evidence.